Ex vivo expansion of CD34-positive peripheral blood progenitor cells from patients with non-Hodgkin's lymphoma: No evidence of concomitant expansion of contaminating bcl2/JH-positive lymphoma cells

Bone Marrow Transplantation

Volumn 26, Issue 5, 2000, Pages 497-503

  Yao, Ming ^a,b   Fouillard, L ^b   Lemoine, F M ^c   Bouchet, S ^b   Firat, H ^d   Andreu, G ^e   Gorin, N C ^b   Douay, L ^d,f   Lopez, M ^a,b  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d ARMAND TROUSSEAU HOSPITAL   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f HÔPITAL SAINT ANTOINE   (France)

Author keywords

Bcl2 JH+ tumour cells; CD34 positive selection; Ex vivo expansion; Non Hodgkin's lymphoma

Indexed keywords

BLEOMYCIN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 3; PREDNISONE; PROTEIN BCL 2; STEM CELL FACTOR; VINDESINE;

ADULT; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; BURST FORMING UNIT E; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CELL PROLIFERATION; CELL SELECTION; CLINICAL ARTICLE; COLONY FORMING UNIT GM; CULTURE MEDIUM; DRUG EFFECT; FEMALE; GROWTH STIMULATION; HEMATOPOIESIS; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MALE; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTO ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL; STEM CELL TRANSPLANTATION;

EID: 0033824490     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702539     Document Type: Article

References (38)

1. Reconstitution of haemopoietic system with autologous marrow taken during relapse and grown in long-term culture
2. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo
3. + cells in autologous stem cell transplantation for breast cancer
4. + cell selection in stroma-free cultures
5. Abrogation of post-myeloablative chemotherapy neutropenia by ex vivo expanded autologous CD34 positive cells
6. Ex vivo expansion of bone marrow progenitor cells for hematopoietic reconstitution following high dose chemotherapy for breast cancer
7. Ex vivo expansion of genetically marked Rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability
8. Bone marrow vs peripheral blood progenitor cells CD34 selection in patients with non-Hodgkin's lymphoma: Different levels of tumour cell reduction. Implications for autografting
9. + cell sorting system
10. + bone marrow progenitor cells in patients with non-Hodgkin's lymphoma
11. Combined positive/negative selection for highly effective purging of PBPC grafts: Towards clinical application in patients with B-CLL
12. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation
13. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate grade or high-grade non-Hodgkin's lymphoma
14. Autologous stem-cell transplantation for non-Hodgkin's lymphomas: The role of graft purging and radiotherapy post-transplantation: Results of a retrospective analysis on 120 patients autografted in a single institution
15. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation
16. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML
17. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells
18. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B cell lymphoma
19. Detection and viability of tumour cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques
20. + cells to remove circulating tumour cells
21. Mobilization of tumour cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors
22. Flt3 ligand, MGDF, Epo and G-CSF enhance ex vivo expansion of hematopoietic cell compartments in the presence of SCF, IL-3 and IL-6
23. The flt3 ligand supports proliferation of lymphohematopoietic progenitors and early B lymphoid progenitors
24. Flk2/flt3 ligand is a potent cofactor for the growth of primitive B cell progenitors
25. Erythropoiesis
26. Characterisation of late and early hematopoietic progenitor/stem cell sensitivity to mafosfamide
27. Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers
28. Haematopoietic defect and decreased expansion potential of bone marow autografts from patients with acute myeloid leukemia in first remission
29. + cells from cord blood
30. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment
31. Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: Less than one log difference between bone marrow and peripheral blood sources
32. + marrow cells for autologous marrow transplantation
33. + progenitors in bone marrow of bcl2-IgH-positive follicular lymphoma patients
34. + cells and their CD19 subsets in patients with follicular
35. Fate of contaminating t(14;18)+ lymphoma cells during ex vivo expansion of CD34-selected hematopoietic progenitor cells
36. + peripheral blood progenitor cells: Implications for expansion of contaminating epithelial tumour cells
37. Ex vivo expansion of bone marrow from breast cancer patients: Reduction in tumor content through passive purging
38. + blood cells in multiple myeloma